In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fellner: Celltech's Revenue-Generating Model Key for Biotech

Executive Summary

Peter Fellner, PhD, recently appointed chairman of British Biotech and outgoing CEO of Celltech Group says more of Europe's biotechs need to do what Celltech has done: find a revenue-generating business model.

You may also be interested in...

Profitability: A Mixed Blessing for Celltech

Celltech's early profits have come from unexciting, low growth specialty pharma products rather than from a breakthrough in its innovative biotechnology pipeline. Now, the challenge for new CEO Göran Ando is to prove that Celltech's focus remains R&D, not specialty pharmaceuticals. With few promising late-stage in-house projects other than CDP 870, generic threats to the revenue source, and the straitjacket that comes with profitability, Ando has plenty on his plate. But his experience, both broadly within the industry and with CDP 870 in particular, suggest he's well placed to take Celltech to a new level of profitability.

CellFactors: Bringing the Commercial to Biotech

When UK cell therapy company CellFactors failed to raise money last year, one of its shareholders stepped in as COO, bringing commercial experience and a customer focus to a group that lacked both. CellFactors is still a risky bet, but its recent progress suggests that European biotechs have much to gain from managers with a track record in other sectors.

CAT Merges for Money; Chooses Well-Dowered OGS

The merger of Cambridge Antibody Technology and Oxford GlycoSciences won't, in the short term, solve many of the problems that both share--namely, a lack of products, scant clinical development capabilities and a non-existent sales and marketing infrastructure. It does, however, create a financially stronger potential acquiror in a European biotech industry in need of consolidation.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts